Luis H. Camacho
The University of Texas MD Anderson Cancer Center · 142 works · 12,189 citations · h-index 34
Top works
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206
- Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
- Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
- Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma
- Leukocytosis and the Retinoic Acid Syndrome in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide
- Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
- Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
- Phase II trial of imatinib mesylate in patients with metastatic melanoma
- Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma
- Presentation and subsequent publication rates of phase I oncology clinical trials
- Biochemotherapy in patients with metastatic anorectal mucosal melanoma
- Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study
- Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer Therapy‐Melanoma questionnaire
- Hepatic Resection for Metastatic Melanoma: Distinct Patterns of Recurrence and Prognosis for Ocular Versus Cutaneous Disease
- Ex vivo blood stimulation assay as a translational research tool in the development of the ticilimumab (CP-675,206)
- Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma
- CTLA ‐4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
- Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome
- Safety and Immunogenicity of Heat-Treated Zoster Vaccine (ZVHT) in Immunocompromised Adults